Product Description
NVL-520 is being developed by Nuvalent for the treatment of Locally Advanced Solid Tumor and Metastatic Solid Tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05118789?term=NVL-520&draw=2&rank=1)
Mechanisms of Action: ROS1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nuvalent
Company Location: CAMBRIDGE MA 02142
Company CEO: James R. Porter
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NVL-520 | P2 |
Unknown Status |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2025-12-21 |
|
| jRCT2031230693 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2025-10-31 |
|
| ARROS-1 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2025-10-31 |
|
| 2021-002477-26 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-09-25 |